{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T10:45:35Z","timestamp":1767091535181},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2016,3,30]],"date-time":"2016-03-30T00:00:00Z","timestamp":1459296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0152362","type":"journal-article","created":{"date-parts":[[2016,3,30]],"date-time":"2016-03-30T22:03:51Z","timestamp":1459375431000},"page":"e0152362","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["A Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8\/14 Serum Complex Levels in Rheumatoid Arthritis Patients"],"prefix":"10.1371","volume":"11","author":[{"given":"S. C.","family":"Nair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. M. J.","family":"Welsing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. Y. K.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Holzinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. W. J.","family":"Bijlsma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"van Laar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. M.","family":"Gerlag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. P. J. G.","family":"Lafeber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. P.","family":"Tak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,3,30]]},"reference":[{"issue":"Suppl 1","key":"ref1","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1478-6354-13-S1-S5","article-title":"Advances in rheumatology: new targeted therapeutics","volume":"13","author":"PP Tak","year":"2011","journal-title":"Arthritis research & therapy"},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"JS Smolen","year":"2014","journal-title":"Annals of the rheumatic diseases"},{"issue":"9194","key":"ref3","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"R Maini","year":"1999","journal-title":"Lancet"},{"issue":"6","key":"ref4","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial","volume":"130","author":"LW Moreland","year":"1999","journal-title":"Annals of internal medicine"},{"issue":"5","key":"ref5","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/ard.2003.013052","article-title":"Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed","volume":"63","author":"LB van de Putte","year":"2004","journal-title":"Annals of the rheumatic diseases"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/art.23383","article-title":"Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study","volume":"58","author":"J Kay","year":"2008","journal-title":"Arthritis and rheumatism"},{"issue":"11","key":"ref7","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/art.23964","article-title":"Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"58","author":"E Keystone","year":"2008","journal-title":"Arthritis and rheumatism"},{"issue":"11","key":"ref8","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"MC Genovese","year":"2005","journal-title":"The New England journal of medicine"},{"issue":"9617","key":"ref9","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"JS Smolen","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"ref10","first-page":"705","article-title":"ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology","volume":"26","author":"AM van Gestel","year":"1999","journal-title":"The Journal of rheumatology"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/rheumatology\/ker300","article-title":"A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm","volume":"51","author":"PP Tak","year":"2012","journal-title":"Rheumatology (Oxford, England)"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"386148","DOI":"10.1155\/2014\/386148","article-title":"Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine","volume":"2014","author":"CI Daien","year":"2014","journal-title":"Mediators of inflammation"},{"key":"ref13","article-title":"MRP8\/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis","author":"IY Choi","year":"2013","journal-title":"Annals of the rheumatic diseases"},{"issue":"8","key":"ref14","doi-asserted-by":"crossref","first-page":"e106253","DOI":"10.1371\/journal.pone.0106253","article-title":"From synovial tissue to peripheral blood: myeloid related protein 8\/14 is a sensitive biomarker for effective treatment in early drug development in patients with rheumatoid arthritis","volume":"9","author":"IY Choi","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"ref15","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1136\/ard.2007.077800","article-title":"Myeloid-related proteins S100A8\/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis","volume":"67","author":"PL van Lent","year":"2008","journal-title":"Annals of the rheumatic diseases"},{"issue":"13","key":"ref16","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2010.375","article-title":"Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial","volume":"303","author":"D Foell","year":"2010","journal-title":"JAMA: the journal of the American Medical Association"},{"issue":"6","key":"ref17","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/annrheumdis-2011-200598","article-title":"The Toll-like receptor 4 agonist MRP8\/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis","volume":"71","author":"D Holzinger","year":"2012","journal-title":"Annals of the rheumatic diseases"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1136\/ard.2011.152496","article-title":"MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes","volume":"70","author":"H Wittkowski","year":"2011","journal-title":"Annals of the rheumatic diseases"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s13075-015-0764-5","article-title":"Serum calprotectin (S100A8\/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis","volume":"17","author":"J Hurnakova","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"ref20","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/ard.2009.119933","article-title":"Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))","volume":"69","author":"P Emery","year":"2010","journal-title":"Annals of the rheumatic diseases"},{"issue":"22","key":"ref21","first-page":"1594","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group","volume":"343","author":"PE Lipsky","year":"2000","journal-title":"The New England journal of medicine"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"ME Weinblatt","year":"2003","journal-title":"Arthritis and rheumatism"},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"ME Weinblatt","year":"1999","journal-title":"The New England journal of medicine"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/ard.2009.126714","article-title":"Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis","volume":"69","author":"M Schoels","year":"2010","journal-title":"Annals of the rheumatic diseases"},{"issue":"2","key":"ref25","first-page":"Cd008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","author":"JA Singh","year":"2011","journal-title":"The Cochrane database of systematic reviews"},{"issue":"9","key":"ref26","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1007\/s00296-011-2033-5","article-title":"Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study","volume":"32","author":"S Kleinert","year":"2012","journal-title":"Rheumatology international"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/ard.2010.133249","article-title":"Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients","volume":"70","author":"LR Coulthard","year":"2011","journal-title":"Annals of the rheumatic diseases"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","article-title":"Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry","volume":"62","author":"ML Hetland","year":"2010","journal-title":"Arthritis and rheumatism"},{"issue":"8","key":"ref29","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/ard.2007.080440","article-title":"The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium","volume":"67","author":"CA Wijbrandts","year":"2008","journal-title":"Annals of the rheumatic diseases"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/art.30136","article-title":"Body mass index and clinical response to infliximab in rheumatoid arthritis","volume":"63","author":"R Klaasen","year":"2011","journal-title":"Arthritis and rheumatism"},{"issue":"8","key":"ref31","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/rheumatology\/ker010","article-title":"The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study","volume":"50","author":"R Klaasen","year":"2011","journal-title":"Rheumatology (Oxford, England)"},{"issue":"10","key":"ref32","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/ard.2003.014647","article-title":"Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement","volume":"63","author":"C Alessandri","year":"2004","journal-title":"Annals of the rheumatic diseases"},{"issue":"12","key":"ref33","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/rheumatology\/kel149","article-title":"Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register","volume":"45","author":"KL Hyrich","year":"2006","journal-title":"Rheumatology (Oxford, England)"},{"issue":"12","key":"ref34","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/rheumatology\/kep314","article-title":"Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis","volume":"48","author":"L Quartuccio","year":"2009","journal-title":"Rheumatology (Oxford, England)"},{"issue":"5","key":"ref35","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.autrev.2010.06.012","article-title":"The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis","volume":"11","author":"M Fabris","year":"2012","journal-title":"Autoimmunity reviews"},{"issue":"3","key":"ref36","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2011-201117","article-title":"Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis","volume":"72","author":"JD Isaacs","year":"2013","journal-title":"Annals of the rheumatic diseases"},{"issue":"6","key":"ref37","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"MH Buch","year":"2011","journal-title":"Annals of the rheumatic diseases"},{"issue":"6","key":"ref38","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/aje\/kwk052","article-title":"Relaxing the rule of ten events per variable in logistic and Cox regression","volume":"165","author":"E Vittinghoff","year":"2007","journal-title":"American journal of epidemiology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0152362","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T23:49:09Z","timestamp":1600386549000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0152362"}},"subtitle":[],"editor":[{"given":"Masataka","family":"Kuwana","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,3,30]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0152362","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,30]]}}}